达拉非尼-话题@MedSci

#达拉非尼#

10篇内容 | 962人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2172655, encodeId=236c21e26557c, content=<a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a> <a href='/topic/show?id=4b0e60250e2' target=_blank style='color:#2F92EE;'>#曲美替尼#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a> <a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=大咖谈 | 达拉非尼联合曲美替尼和奥希替尼治疗EGFR合并BRAF V600E突变NSCLC一例, objectType=article, longId=803212, objectId=4d44803212b3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/senior-doctor-at-workplace-VQC5M89.jpg, objectUrl=/article/show_article.do?id=4d44803212b3, replyNumber=0, likeNumber=38, createdTime=2023-12-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4d44803212b3, moduleTitle=大咖谈 | 达拉非尼联合曲美替尼和奥希替尼治疗EGFR合并BRAF V600E突变NSCLC一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d44803212b3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1413146, encodeId=392a141314625, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=J Clin Oncol：Spartalizumab 联合达拉非尼和曲美替尼治疗黑色素瘤的疗效, objectType=article, longId=729628, objectId=bf1ee296289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1ee296289d, replyNumber=0, likeNumber=37, createdTime=2022-06-17, rootId=0, userName=zhangjiqing, userId=f31c2942374, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1ee296289d, moduleTitle=J Clin Oncol：Spartalizumab 联合达拉非尼和曲美替尼治疗黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1ee296289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413145, encodeId=04761413145be, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, objectType=article, longId=301601, objectId=430a301601f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=430a301601f4, replyNumber=0, likeNumber=37, createdTime=2022-03-26, rootId=0, userName=zhangjiqing, userId=f31c2942374, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=430a301601f4, moduleTitle=“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=430a301601f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413144, encodeId=c83b14131443e, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=27, createdTime=2022-01-17, rootId=0, userName=zhangjiqing, userId=f31c2942374, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413143, encodeId=04ff141314365, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=J Thorac Oncol：达拉非尼+曲美替尼治疗转移性BRAF V600E突变非小细胞肺癌的疗效：5年生存结果更新, objectType=article, longId=217037, objectId=f9ca21e03751, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9ca21e03751, replyNumber=0, likeNumber=42, createdTime=2021-09-15, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9ca21e03751, moduleTitle=J Thorac Oncol：达拉非尼+曲美替尼治疗转移性BRAF V600E突变非小细胞肺癌的疗效：5年生存结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9ca21e03751)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413142, encodeId=9ce2141314220, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, objectType=article, longId=215840, objectId=dfc62158401b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc62158401b, replyNumber=0, likeNumber=37, createdTime=2021-08-18, rootId=0, userName=zhangjiqing, userId=f31c2942374, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc62158401b, moduleTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc62158401b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413141, encodeId=6ff614131413a, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=Eur J Cancer：一半多的达拉非尼联合曲美替尼治疗的患者会经历发热！, objectType=article, longId=214062, objectId=752921406216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=752921406216, replyNumber=0, likeNumber=40, createdTime=2021-07-13, rootId=0, userName=zhangjiqing, userId=f31c2942374, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=752921406216, moduleTitle=Eur J Cancer：一半多的达拉非尼联合曲美替尼治疗的患者会经历发热！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=752921406216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413140, encodeId=acd114131407e, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=Lancet oncol：达拉非尼联合曲美替尼治疗BRAF V600E突变的胆管癌, objectType=article, longId=199739, objectId=ef2c199e3957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef2c199e3957, replyNumber=0, likeNumber=32, createdTime=2020-08-22, rootId=0, userName=zhangjiqing, userId=f31c2942374, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef2c199e3957, moduleTitle=Lancet oncol：达拉非尼联合曲美替尼治疗BRAF V600E突变的胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef2c199e3957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413139, encodeId=9f501413139aa, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=从疗效到机制，达拉非尼+曲美替尼治疗中国黑色素瘤患者更具优势, objectType=article, longId=184053, objectId=2bb91840533a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bb91840533a, replyNumber=0, likeNumber=37, createdTime=2019-12-04, rootId=0, userName=zhangjiqing, userId=f31c2942374, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bb91840533a, moduleTitle=从疗效到机制，达拉非尼+曲美替尼治疗中国黑色素瘤患者更具优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bb91840533a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413138, encodeId=beb814131387e, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=Lancet oncol：新辅助药物达拉非尼联合曲美替尼疗法用于III期黑色素瘤的疗效评估, objectType=article, longId=167652, objectId=245216e65298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=245216e65298, replyNumber=0, likeNumber=32, createdTime=2019-06-06, rootId=0, userName=zhangjiqing, userId=f31c2942374, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=245216e65298, moduleTitle=Lancet oncol：新辅助药物达拉非尼联合曲美替尼疗法用于III期黑色素瘤的疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=245216e65298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1413137, encodeId=60b9141313e49, content=<a href='/topic/show?id=578993933d0' target=_blank style='color:#2F92EE;'>#达拉非尼#</a>, objectTitle=【ASCO-GI 2019】抢先看！达拉非尼联合曲美替尼在BRAF V600E突变的胆管癌患者中的研究, objectType=article, longId=158427, objectId=4af815842edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4af815842edc, replyNumber=0, likeNumber=38, createdTime=2019-01-20, rootId=0, userName=zhangjiqing, userId=f31c2942374, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4af815842edc, moduleTitle=【ASCO-GI 2019】抢先看！达拉非尼联合曲美替尼在BRAF V600E突变的胆管癌患者中的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4af815842edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

达拉非尼

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#EGFR# #BRAF# #曲美替尼# #奥希替尼# #达拉非尼#

大咖谈 | 达拉非尼联合曲美替尼和奥希替尼治疗EGFR合并BRAF V600E突变NSCLC一例

2023-12-03发表于上海

zhangjiqing (审核中...)

前往app查看评论内容

#达拉非尼#

J Clin Oncol：Spartalizumab 联合达拉非尼和曲美替尼治疗黑色素瘤的疗效

2022-06-17

zhangjiqing (审核中...)

前往app查看评论内容

#达拉非尼#

“双靶组合”新适应症在我国获批，「达拉非尼」联合「曲美替尼」为BRAF V600突变型非小细胞肺癌患者带来新选择

2022-03-26

zhangjiqing (审核中...)

前往app查看评论内容

#达拉非尼#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-01-17

zhouqu_8 (审核中...)

前往app查看评论内容

#达拉非尼#

J Thorac Oncol：达拉非尼+曲美替尼治疗转移性BRAF V600E突变非小细胞肺癌的疗效：5年生存结果更新

2021-09-15

zhangjiqing (审核中...)

前往app查看评论内容

#达拉非尼#

Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后

2021-08-18

zhangjiqing (审核中...)

前往app查看评论内容

#达拉非尼#

Eur J Cancer：一半多的达拉非尼联合曲美替尼治疗的患者会经历发热！

2021-07-13

zhangjiqing (审核中...)

前往app查看评论内容

#达拉非尼#

Lancet oncol：达拉非尼联合曲美替尼治疗BRAF V600E突变的胆管癌

2020-08-22

zhangjiqing (审核中...)

前往app查看评论内容

#达拉非尼#

从疗效到机制，达拉非尼+曲美替尼治疗中国黑色素瘤患者更具优势

2019-12-04

zhangjiqing (审核中...)

前往app查看评论内容

#达拉非尼#

Lancet oncol：新辅助药物达拉非尼联合曲美替尼疗法用于III期黑色素瘤的疗效评估

2019-06-06

zhangjiqing (审核中...)

前往app查看评论内容

#达拉非尼#

【ASCO-GI 2019】抢先看！达拉非尼联合曲美替尼在BRAF V600E突变的胆管癌患者中的研究

2019-01-20

科室
- - 订阅+
  - 更多科室
工具
服务